Komori
Share Issuance and Disposal190AChordia Therapeutics Inc.Pharmaceuticals

Notice Regarding the Large-Scale Exercise of the Ninth Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms)

A total of 11,760 Ninth Series Stock Acquisition Rights were exercised between 1 April and 20 April 2026, resulting in the delivery of 1,176,000 shares. The number of unexercised stock acquisition rights at the end of the period was 34,324.

Worth reading
69In focus
Scored from 2 of 5 sections
Direction
Neutral
Direction inferred from the company’s description.
Scale
1176000
Shares
Wording
Definitive
How definitive the wording is.

Details of issuance or disposal

Bulk exercise of the Ninth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)

Who receives how much1,176,000Shares

Shares delivered since the beginning of the month: 1,176,000 shares (all newly issued shares; no treasury shares transferred)

株式会社SBI証券 (the allottee at the time of issuance on 22 September 2025)

The lower thin line represents the existing number of shares to which these shares will be added.

発行済株式総数

The ratio of shares issued through exercises since the beginning of the month to the total number of issued shares is not stated in the body of the disclosure

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
With an exercise price adjustment clause. The exercise prices during the period were ¥116, ¥123, ¥118, ¥119, ¥122, ¥121, ¥124, ¥131 and ¥134 per share. The adjustment floor was not disclosed
Number of Stock Acquisition Rights
Total issued: 103,200 stock acquisition rights. Unexercised balance as of 20 April: 34,324 (46,084 as of the end of the preceding month)
Most recent equity financing
Timing 22 September 2025 / Type Issuance through a third-party allotment of the Ninth Series of Stock Acquisition Rights (with exercise price adjustment clause) and the Tenth and Eleventh Series of Stock Acquisition Rights / Amount Not disclosed
Details of issuance or disposal
ItemDetails
Type of issuance or disposalBulk exercise of the Ninth Series of Stock Acquisition Rights issued through a third-party allotment (with exercise price adjustment clause)
Number of shares to be issued or disposed ofShares delivered since the beginning of the month: 1,176,000 shares (all newly issued shares; no treasury shares transferred)
Intended allottee株式会社SBI証券 (the allottee at the time of issuance on 22 September 2025)
Dilution RateThe ratio of shares issued through exercises since the beginning of the month to the total number of issued shares is not stated in the body of the disclosure
Total number of issued shares75,216,400 shares (as of the end of the month preceding the month covered) → Not disclosed
Exercise priceWith an exercise price adjustment clause. The exercise prices during the period were ¥116, ¥123, ¥118, ¥119, ¥122, ¥121, ¥124, ¥131 and ¥134 per share. The adjustment floor was not disclosed
Number of Stock Acquisition RightsTotal issued: 103,200 stock acquisition rights. Unexercised balance as of 20 April: 34,324 (46,084 as of the end of the preceding month)
Most recent equity financingTiming 22 September 2025 / Type Issuance through a third-party allotment of the Ninth Series of Stock Acquisition Rights (with exercise price adjustment clause) and the Tenth and Eleventh Series of Stock Acquisition Rights / Amount Not disclosed
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioProcedures under the Corporate Code of ConductMajor shareholders after the offeringImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the bulk exercise of the stock acquisition rights during the period from 1 April to 20 April 2026.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Large-Scale Exercise of the Ninth Series of Stock Acquisition Rights Issued Through a Third-Party Allotment (with Exercise Price Adjustment Terms) | Chordia Therapeutics Inc. (190A) timely disclosure | Komori